Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

SIGA Technologies (NASDAQ:SIGA) declares another dividend >

Jyoti Prakash, CFA | Healthcare | Comment | 2 days ago

SynAct Pharma (STO: SYNACT) initiates the Phase II RESOVIR-2 study in dengue >

Jyoti Prakash, CFA | Healthcare | Comment | 3 days ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.04

— 0.00 (−2.78)

As at 28/03/2026

Market capitalisation: AUD126m

Equities

Equities by Sector

Sectors

Thematics

Latest

Stock of the month – March

Edison and Aquis: Insights from Aquis class of 2025 celebration

Edison explains: AI for insurance brokers and platforms – threat or opportunity?

Audiovisual

Latest

In conversation with Keith Smith of IntelliAM AI

Sirma – executive interview

Patria Private Equity Trust in 60 seconds

About Edison

Corporates

Investors

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.04

Actinogen Medical — XanaMIA passes interim analysis and marches on

Actinogen Medical — XanaMIA passes first safety milestone

Actinogen Medical — XanaMIA recruitment exceeds expectations

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.39

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Alzinova (ALZ)

SEK0.59

Webinar: The CNS renaissance Biotech companies at the forefront

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP0.33

Argent Biopharma (RGT)

AUD0.04

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF52.60

Basilea Pharmaceutica — BAL2420 clinical entry expands antibiotic pipeline

Basilea Pharmaceutica — An emphatic start to 2026

Basilea Pharmaceutica — BARDA backs latest antibacterial programme

See morecontent on

Biomea Fusion (BMEA)

USD1.32

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

BioVersys (BIOV)

CHF30.00

BioVersys — A step-change year for development activity

Bull, Bear & Beyond – BioVersys: executive interview

BioVersys — Poised to unlock value in critical AMR

See morecontent on

Cantargia (CANTA)

SEK3.98

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK7.67

Cereno Scientific – Leadership perspectives from the capital markets day

Cereno Scientific — Inflection points coming into view

Cereno Scientific – The investment case: capital markets day highlights

See morecontent on

Chosa (CHOSA)

SEK0.85

CHOSA Oncology – executive interview

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

See morecontent on

Creo Medical (CREO)

GBP0.12

Creo Medical — FY25 results validate growth strategy

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on